CN110123763A - 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 - Google Patents

靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 Download PDF

Info

Publication number
CN110123763A
CN110123763A CN201910470369.1A CN201910470369A CN110123763A CN 110123763 A CN110123763 A CN 110123763A CN 201910470369 A CN201910470369 A CN 201910470369A CN 110123763 A CN110123763 A CN 110123763A
Authority
CN
China
Prior art keywords
constituent
indigo red
less
particle
indigo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910470369.1A
Other languages
English (en)
Chinese (zh)
Inventor
吴斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satodam Corp
Original Assignee
Phosphorex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosphorex Inc filed Critical Phosphorex Inc
Publication of CN110123763A publication Critical patent/CN110123763A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910470369.1A 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 Pending CN110123763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662469P 2012-06-21 2012-06-21
US61/662,469 2012-06-21
CN201380043697.4A CN104602675B (zh) 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380043697.4A Division CN104602675B (zh) 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法

Publications (1)

Publication Number Publication Date
CN110123763A true CN110123763A (zh) 2019-08-16

Family

ID=49769412

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910470369.1A Pending CN110123763A (zh) 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
CN201380043697.4A Active CN104602675B (zh) 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380043697.4A Active CN104602675B (zh) 2012-06-21 2013-06-21 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法

Country Status (6)

Country Link
US (3) US10039829B2 (enExample)
EP (2) EP3597178A1 (enExample)
JP (5) JP6382187B2 (enExample)
CN (2) CN110123763A (enExample)
CA (1) CA2914782C (enExample)
WO (1) WO2013192493A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition
RU2630561C2 (ru) * 2015-10-20 2017-09-11 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Способ получения водно-солевых дисперсий фуллерена
CN115969814A (zh) * 2017-03-29 2023-04-18 法斯瑞斯公司 含有靛玉红及其衍生物的新颖药物制剂以及制造和使用该药物制剂的方法
RU2721318C1 (ru) * 2019-02-28 2020-05-18 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ получения золей и суспензий
JP2022531012A (ja) * 2019-05-03 2022-07-05 アゾーラ セラピューティクス，インコーポレイテッド インジゴ及び／又はインジゴ誘導体を含む組成物並びにその使用の方法
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160118A (zh) * 2005-02-24 2008-04-09 依兰药物国际有限公司 多西紫杉醇或其类似物的纳米微粒制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929242A (en) * 1986-11-26 1990-05-29 Baxter International Inc. Solution and method for maintaining patency of a catheter
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
JP2005516938A (ja) * 2001-12-13 2005-06-09 ナトロジェン・セラピューティクス・インコーポレーテッド イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
CN1615852A (zh) * 2003-11-10 2005-05-18 许军 靛玉红口服滴丸及制备工艺
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
CA2602341A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
MX2007012762A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
ES2532089T3 (es) 2005-06-02 2015-03-24 Ipsen Biopharmaceuticals, Inc. GH e IGF-1 para el tratamiento de trastornos del crecimiento
CN101023944A (zh) * 2006-02-23 2007-08-29 黎明涛 靛玉红衍生物在制备治疗神经退行性变疾病药物中的应用
CN101074229B (zh) * 2007-06-08 2010-09-01 无锡杰西医药科技有限公司 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
PL2113253T3 (pl) 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
CN101362066B (zh) * 2008-09-27 2010-12-22 同济大学 脂质体包埋量子点的二氧化硅微球的制备方法及其产品
CN101775082B (zh) * 2010-02-09 2012-06-27 中国药科大学 基于两性离子的电荷反转型壳聚糖衍生物及其在药剂中的应用
CN102018736B (zh) * 2010-11-19 2012-03-28 成都中医药大学 一种青黛饮片及其制备方法
CN102228433B (zh) * 2011-06-29 2012-11-28 上海中医药大学 过饱和自微乳制剂及其制备方法和应用
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160118A (zh) * 2005-02-24 2008-04-09 依兰药物国际有限公司 多西紫杉醇或其类似物的纳米微粒制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
严素芳: "靛玉红治疗银屑病四十三例临床观察", 《云南中医杂志》 *
杨弈: "靛玉红衍生物（indirubin-3’-oxime，IO）保护神经元的作用及机制研究", 《博士学位论文》 *
蒋苹等: "靛玉红固体分散体的制备及其体外溶出研究", 《第三军医大学学报》 *

Also Published As

Publication number Publication date
JP2018199685A (ja) 2018-12-20
EP2863897A1 (en) 2015-04-29
EP2863897B1 (en) 2019-06-19
CA2914782C (en) 2021-05-25
US10675350B2 (en) 2020-06-09
US20150110878A1 (en) 2015-04-23
EP2863897A4 (en) 2016-01-27
JP2015520241A (ja) 2015-07-16
JP2023062070A (ja) 2023-05-02
EP3597178A1 (en) 2020-01-22
CN104602675B (zh) 2019-06-28
WO2013192493A1 (en) 2013-12-27
US20220168423A1 (en) 2022-06-02
CA2914782A1 (en) 2013-12-27
JP2020073564A (ja) 2020-05-14
JP2021181447A (ja) 2021-11-25
CN104602675A (zh) 2015-05-06
JP6382187B2 (ja) 2018-08-29
US10039829B2 (en) 2018-08-07
US20190054174A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JP4838514B2 (ja) 低粘度液体剤形
DE60319073T2 (de) Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
DE60222160T2 (de) Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
JP4776233B2 (ja) 摩損しにくくかつプルランを含む速崩壊性固形製剤
CN110123763A (zh) 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
US20080152585A1 (en) Low viscosity liquid dosage forms
JP2009543797A (ja) ナノ粒子ソラフェニブ製剤
JP2009508859A (ja) ナノ粒子アリピプラゾール製剤
BRPI0613540A2 (pt) formulações de imatinib mesilato nanoparticuladas
JP2005529911A (ja) ナノ粒子ナイスタチン製剤
JP2009507925A (ja) ナノ粒子タダラフィル製剤
MX2007008212A (es) Formulaciones de candesartan en nanoparticulas.
KR20080017065A (ko) 나노입자형 아세트아미노펜 제제
JP2021535094A (ja) 注射可能な医薬組成物およびその調製方法
CN109394685B (zh) 一种vegfr抑制剂的药物组合物及其制备方法
JP2008543862A (ja) ナノ粒子アゼルニジピン製剤
KR20170110285A (ko) 엘로티닙 나노입자 및 그 제조방법, 및 엘로티닙 나노입자를 함유하는 약학 조성물
CN113521292A (zh) 一种cox-2抑制剂和曲马多的复方制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230918

Address after: Massachusetts

Applicant after: Satodam Corp.

Address before: Massachusetts

Applicant before: PHOSPHOREX, Inc.